Panbela Therapeutics, Inc.

PBLA · OTC
Analyze with AI
9/30/2024
6/30/2024
3/31/2024
12/31/2023
Operating Activities
Net Income-$7,179-$7,140-$7,120-$6,474
Dep. & Amort.$0$0$0$0
Deferred Tax$0$0$0$0
Stock-Based Comp.$0$0$103$124
Change in WC-$4,472$6,881-$2,409$3,204
Other Non-Cash$9,531-$722$34$66
Operating Cash Flow-$2,120-$981-$9,392-$3,080
Investing Activities
PP&E Inv.$0$0$0$0
Net Acquisitions$0$0$0-$400
Inv. Purchases$0$0$0$0
Inv. Sales/Matur.$0$0$0$0
Other Inv. Act.$0$0$0-$7,569
Investing Cash Flow$0$0$0-$7,969
Financing Activities
Debt Repay.$2,200$0-$1,000$0
Stock Issued$0$0$8,082$4,749
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$0$0$0$4,758
Financing Cash Flow$2,200$0$7,082$4,749
Forex Effect$3$3-$6$2
Net Chg. in Cash$83-$203-$2,316$1,671
Supplemental Information
Beg. Cash$59$262$2,578$907
End Cash$142$59$262$2,578
Free Cash Flow-$2,120-$981-$9,392-$3,080
Panbela Therapeutics, Inc. (PBLA) Financial Statements & Key Stats | AlphaPilot